Australia is entering a new era of ageing. By 2026, life expectancy is projected to reach 84.3 years – among the highest worldwide. But longevity comes with urgency: dementia, including Alzheimer’s disease, is now Australia’s leading cause of death, accounting for 9.4% of all fatalities.

More than 446,000 Australians are currently living with dementia – a number set to exceed one million by 2065. Yet despite awareness campaigns, too many people are diagnosed too late.

WHEN MEMORY LOSS GETS DISMISSED AS “NORMAL”

Early Alzheimer’s often presents subtly: memory lapses, confusion, or behavioural changes. Families notice, patients downplay, and even clinicians can struggle to distinguish these signs from normal ageing without targeted assessment.

The result is a persistent diagnosis gap: years of unaddressed symptoms before formal evaluation.

THE COST OF DELAY

Normalising cognitive decline delays access to:

• Support services and care planning;
• Emerging disease-modifying therapies; and
• Interventions that can slow disease progression.

Nearly 70% of dementia-related deaths occur in people aged over 75 years, reflecting the link between ageing populations and dementia risk.

Unlike heart disease or cancer, cognitive decline is yet to be integrated into routine health conversations.

COGNITIVE DECLINE DEMANDS URGENT ACTION

Barriers to early detection are often cultural and communication-driven:

• Families hesitate to raise concerns for fear of stigma; and
• Individuals worry about being labelled or losing independence.

Australia has shown that early detection saves lives, from cardiovascular screening to cancer care. Cognitive decline deserves the same proactive approach: recognise, measure, and act before daily life is disrupted.

Emerging therapies are only effective in early stages, making timely diagnosis critical. Delayed recognition is no longer acceptable, or inevitable.

BRIDGING THE GAP: EARLY DETECTION MATTERS

Industry leaders, clinicians, and healthcare systems must:

• Recognise early symptoms promptly;
• Encourage patients to seek timely medical consultation; and
• Ensure smooth referral to specialist care.

Closing the diagnosis gap isn’t just about medicine – it’s about communication. Public messaging shapes how people interpret symptoms and decide when to act.

A CHRONIC DISEASE THAT CAN NO LONGER BE NORMALISED

As Australia’s population ages, dementia and Alzheimer’s disease increasingly affect families, carers, and the health system. Yet unlike other chronic diseases, Alzheimer’s is still surrounded by uncertainty. Conversations about cognitive decline are often avoided – families fear causing distress, and individuals worry about stigma or loss of independence.

This cultural discomfort fuels delayed diagnosis. Alzheimer’s disease must be treated with the same urgency as heart disease, cancer, or diabetes, and cognitive health should be a routine part of medical conversations – not addressed only when symptoms become severe.

WHY EARLY DETECTION MATTERS MORE THAN EVER

Emerging therapies for early-stage Alzheimer’s are transforming care, but only for patients diagnosed before functional decline.

Primary care clinicians, healthcare systems, and industry stakeholders now have a clear mandate to:

• Recognise early symptoms promptly
• Encourage timely medical consultation
• Ensure seamless referral to specialist care

Delayed recognition is no longer acceptable, or inevitable.

CLOSING THE GAP BETWEEN SYMPTOMS AND DIAGNOSIS

The emergence of disease-modifying therapies highlights a critical truth: timely diagnosis is no longer optional. Many treatments are effective only in the early symptomatic phase, making delays costly for patients and families.

Closing this gap requires:

• Improved recognition of early cognitive changes by patients, families, and clinicians;
• Confidence in seeking medical advice at the first sign of concern; and
• Equipping primary care clinicians with tools to identify potential symptoms and navigate appropriate referral pathways.

Early action is essential. The opportunity to intervene and improve outcomes exists, but only for those diagnosed in time.

COMMUNICATION: A CRITICAL TOOL

Alzheimer’s disease is medically complex, but many barriers to progress are strategic and communication-driven. As Australia’s population ages, awareness, education, and early engagement will determine whether patients are diagnosed in time to benefit from emerging therapies.

Strategic messaging can:

• Position cognitive health as part of overall wellbeing;
• Improve recognition of early symptoms;
• Reduce stigma and normalise conversations;
• Empower families and carers to act proactively; and
• Increase the impact of emerging therapies.

For pharma and biotech leaders, communication isn’t just awareness – it shapes patient pathways, accelerates early diagnosis, and enables adoption of innovative treatments.

FROM AWARENESS TO ACTION

Memory loss is not an inevitable part of ageing. Early cognitive changes are signals that demand attention, conversation, and clinical evaluation.

At VIVA! Communications, we partner with healthcare organisations, advocacy groups, and pharmaceutical leaders across APAC to translate complex science into clear, culturally relevant narratives.

The challenge for industry leaders is clear:

How is your organisation driving early recognition, reducing stigma, and empowering patients to act, before it’s too late?

The time to move from awareness to action is now.